Mechanisms of DNA damage-induced, p53-dependent repression of the Cdc25C Phosphat
DNA 损伤诱导的、p53 依赖性的 Cdc25C 磷酸盐抑制机制
基本信息
- 批准号:8537529
- 负责人:
- 金额:$ 3.71万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-11-16 至 2012-06-19
- 项目状态:已结题
- 来源:
- 关键词:AddressApoptosisBerylliumBindingBinding SitesBoxingCancer PatientCdc25C proteinCell CycleCell Cycle CheckpointCell Cycle ProgressionCell DeathCellsCellular StressConsensusCyclin-Dependent KinasesDNADNA BindingDNA DamageDNA MethyltransferaseDNA Modification MethylasesDNA Repair PathwayDependenceDown-RegulationDoxorubicinElementsG2/M TransitionGC Rich SequenceGene TargetingGenesGenetic TranscriptionGenomeHistonesHumanHypoxiaIndiumLeadMalignant NeoplasmsMammalian CellMediatingMethodsMolecularMolecular AnalysisMolecular TargetMutateOncogene ActivationPharmaceutical PreparationsPhosphoric Monoester HydrolasesPhysiologicalPlayProtein FamilyProtein p53Relative (related person)RepressionResponse ElementsRoleSystemTranscriptional ActivationTumor Suppressor Proteinsbasecancer cellgene repressionneoplastic cellnovel therapeutic interventiononcoprotein p21overexpressionpromoterpublic health relevanceresponsesenescencetherapeutic targettooltranscription factortumorigenesis
项目摘要
DESCRIPTION (provided by applicant): The tumor suppressor p53 is the most commonly mutated gene found in human cancers [3]. It plays a vital role in guarding mammalian cells against tumorigenesis [22,23]. The Cdc25C phosphatase plays an important role in cell cycle progression at the G2/M transition [7-10]. Its activity is inhibited in response to DNA damage thereby contributing to the G2 checkpoint response [7-10]. Cdc25C is a target for transcriptional repression by p53. Overexpression of Cdc25C sensitizes cancer cells to DNA damage induced cell death [11, 12]. Interestingly, normal untransformed cells are not sensitized to this treatment [12]. Therefore, Cdc25C repression inhibition could lead to a novel therapeutic approach in combination with DNA damage. In order to address this possibility, a clear molecular basis for p53-dependent repression of Cdc25C must be described. As of yet, three distinct mechanisms of repression have been proposed, one involving direct binding to DNA by p53 and two indirect involving different elements. Each of which may provide molecular targets for inhibition. The present study aims to dissect the molecular basis for p53-dependent repression of Cdc25C and to explore its relevance as a tool that can be exploited in order to enhance chemotherapeutic responses in cancer patients. Hypothesis: It is hypothesized that the p53 response element is required in order for p53 to bind to the Cdc25C promoter and for the recruitment of co-repressors. Additional factors, such as p21, may be required for this repression. Furthermore, inhibition of this mechanism in cancer cells can abrogate DNA damage-induced Cdc25C repression, which results in heightened sensitivity to DNA damage-induced cell death. Specific Aims: Aim 1: Analysis of the molecular basis for DNA damage-induced p53-dependent repression of Cdc25C. A) Characterize the role of Histone Deacetylases (HDACs) and DNA methyltransferases (DNMTs) in Cdc25C repression. B) Study the role of CCAAT box binding factor, NF-Y in p53-dependent repression of Cdc25C. Aim 2: Functional analysis of different elements in the Cdc25C promoter. A) Characterize relevant elements in the Cdc25C promoter in order to identify potential therapeutic targets. B) Explore methods to use Cdc25C repression inhibition as a novel therapeutic approach. Aim 3: Study of the role of p21 in the p53-induced repression of Cdc25C. A) Investigate the p21 dependence of p53 and co-repressor recruitment to the Cdc25C promoter. B) Study the role of Rb family proteins in Cdc25C mediated repression in response to DNA damage.
PUBLIC HEALTH RELEVANCE: The present study aims to dissect the molecular basis for p53-dependent repression of Cdc25C and to explore its relevance as a tool that can be exploited in order to enhance chemotherapeutic responses in cancer patients.
描述(由申请人提供):肿瘤抑制基因p53是人类癌症中最常见的突变基因[3]。它在保护哺乳动物细胞免受肿瘤发生方面起着至关重要的作用[22,23]。Cdc 25 C磷酸酶在G2/M转换的细胞周期进展中起重要作用[7-10]。其活性在响应DNA损伤时被抑制,从而促进G2检查点响应[7-10]。Cdc 25 C是p53转录抑制的靶点。Cdc 25 C的过表达使癌细胞对DNA损伤诱导的细胞死亡敏感[11,12]。有趣的是,正常的未转化细胞对这种治疗不敏感[12]。因此,Cdc 25 C阻遏抑制可能导致与DNA损伤组合的新的治疗方法。为了解决这种可能性,一个明确的分子基础p53依赖性抑制Cdc 25 C必须加以描述。到目前为止,已经提出了三种不同的抑制机制,一种涉及p53与DNA的直接结合,两种涉及不同元件的间接结合。每一种都可以提供用于抑制的分子靶标。本研究的目的是剖析p53依赖性抑制Cdc 25 C的分子基础,并探讨其相关性作为一种工具,可以利用,以提高癌症患者的化疗反应。假设:假设p53应答元件是p53与Cdc 25 C启动子结合和募集共阻遏物所必需的。其他因素,如p21,可能需要这种抑制。此外,在癌细胞中抑制这种机制可以消除DNA损伤诱导的Cdc 25 C抑制,这导致对DNA损伤诱导的细胞死亡的敏感性提高。特定目的:目的1:分析DNA损伤诱导的Cdc 25 C p53依赖性抑制的分子基础。 A)表征组蛋白脱乙酰酶(HDAC)和DNA甲基转移酶(DNMT)在Cdc 25 C阻遏中的作用。 B)研究CCAAT盒结合因子NF-γ在Cdc 25 C的p53依赖性阻遏中的作用。目的2:Cdc 25 C启动子不同元件的功能分析。 A)表征Cdc 25 C启动子中的相关元件以鉴定潜在的治疗靶标。 B)探索使用Cdc 25 C阻遏抑制作为新的治疗方法的方法。目的3:研究p21在p53抑制Cdc 25 C中的作用。A)研究p53和共阻遏物募集到Cdc 25 C启动子的p21依赖性。B)研究Rb家族蛋白在Cdc 25 C介导的响应于DNA损伤的阻遏中的作用。
公共卫生关系:本研究的目的是剖析p53依赖性抑制Cdc 25 C的分子基础,并探讨其相关性作为一种工具,可以利用,以提高癌症患者的化疗反应。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Luis A. Carvajal其他文献
SYK Inhibitors, Entospletinib and Lanraplenib, Show Potent Anti-Leukemic Activity in Combination with Targeted Agents
- DOI:
10.1182/blood-2022-159087 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Luis A. Carvajal;Michael McKeown;Tressa Hood;Pavan Kumar;Douglas C. Saffran;Jorge DiMartino - 通讯作者:
Jorge DiMartino
Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for emNPM1/emm Patients Achieving MRD-Negative CR after Intensive Induction
- DOI:
10.1182/blood-2022-159212 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:23.100
- 作者:
Konstanze Döhner;Hartmut Döhner;Daniela Weber;Silke Kapp-Schwoerer;Amanda Gilkes;Ian Thomas;Sean Johnson;Nicola Potter;Yana Bevan;Jad Othman;Nigel H. Russell;Christoph Röllig;Christian Thiede;Martin Bornhaeuser;Thomas Oellerich;Jenna Elder;Luis A. Carvajal;Zung To;Jorge DiMartino;Richard Dillon - 通讯作者:
Richard Dillon
KB-Lanra 1001: A Phase 1b/2 Study of Safety, PK, PD, and Preliminary Efficacy of the Selective SYK Inhibitor Lanraplenib in Combination with the FLT3 Inhibitor Gilteritinib in FLT3-Mutated R/R AML
- DOI:
10.1182/blood-2023-178804 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Monteserrat Arnan;Anand Ashwin Patel;Jordi Esteve;Lawrence Morris;Gary J. Schiller;Ronan T. Swords;Juan M. Alonso-Dominguez;Laura C. Michaelis;Naval Daver;Luis A. Carvajal;Gordon Bray;Elizabeth Olek;Richard E. Cutler;Jorge F. DiMartino;Eytan M. Stein - 通讯作者:
Eytan M. Stein
OA-32 p300 Catalytic Inhibition Selectively Disrupts IRF4 Oncogenic Programs Impacting Multiple Myeloma Cell Growth and Survival
- DOI:
10.1016/s2152-2650(24)01873-1 - 发表时间:
2024-09-01 - 期刊:
- 影响因子:
- 作者:
Michael R. McKeown;Giulia Giorgetti;Walter F. Lenoir;Marek Kobylarz;Tamara Hopkins;Wayne Glore;Michelle G. Shum;Elena Maroto Martín;Kenneth Wen;Hizra Farrukh;Kameron R. Mori;Hua Gao;Luis A. Carvajal;Nikolaus Obholzer;Benjamin Trotter;Christopher Dinsmore;Nikhil Munshi;Peter Rahl;Charles Lin;Mariateresa Fulciniti - 通讯作者:
Mariateresa Fulciniti
The Combination of Lanraplenib, a Selective SYK Inhibitor, and Gilteritinib, a FLT3 Inhibitor, Targets Aberrant Proliferation and Differentiation Blockade in Acute Myeloid Leukemia
- DOI:
10.1182/blood-2023-186605 - 发表时间:
2023-11-02 - 期刊:
- 影响因子:
- 作者:
Luis A. Carvajal;Michael R. McKeown;Tressa Hood;Linlin Guo;Charles Y. Lin;Jorge F. DiMartino - 通讯作者:
Jorge F. DiMartino
Luis A. Carvajal的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Luis A. Carvajal', 18)}}的其他基金
Mechanisms of DNA damage-induced, p53-dependent repression of the Cdc25C Phosphat
DNA 损伤诱导的、p53 依赖性的 Cdc25C 磷酸盐抑制机制
- 批准号:
7914522 - 财政年份:2010
- 资助金额:
$ 3.71万 - 项目类别:
相似国自然基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
- 批准号:LBY21H010001
- 批准年份:2020
- 资助金额:0.0 万元
- 项目类别:省市级项目
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
- 批准号:81703335
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
- 批准号:81670594
- 批准年份:2016
- 资助金额:58.0 万元
- 项目类别:面上项目
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
- 批准号:81470791
- 批准年份:2014
- 资助金额:73.0 万元
- 项目类别:面上项目
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
- 批准号:81301123
- 批准年份:2013
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
- 批准号:81101529
- 批准年份:2011
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
- 批准号:39500043
- 批准年份:1995
- 资助金额:9.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Milk fat globule-EGF factor 8 and hepatocyte apoptosis-induced liver wound healing response
乳脂肪球-EGF因子8与肝细胞凋亡诱导的肝脏创面愈合反应
- 批准号:
10585802 - 财政年份:2023
- 资助金额:
$ 3.71万 - 项目类别:
Development of an apoptosis biosensor for monitoring of breast cancer
开发用于监测乳腺癌的细胞凋亡生物传感器
- 批准号:
10719415 - 财政年份:2023
- 资助金额:
$ 3.71万 - 项目类别:
Interrogating the Fgl2-FcγRIIB axis on CD8+ T cells: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
询问 CD8 T 细胞上的 Fgl2-FcγRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10605856 - 财政年份:2023
- 资助金额:
$ 3.71万 - 项目类别:
Novel targeted therapy for FGFR inhibitor-resistant urothelial cancer and apoptosis based therapy for urothelial cancer
FGFR抑制剂耐药性尿路上皮癌的新型靶向治疗和基于细胞凋亡的尿路上皮癌治疗
- 批准号:
23K08773 - 财政年份:2023
- 资助金额:
$ 3.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Mechanistic analysis of apoptosis induction by HDAC inhibitors in head and neck cancer
HDAC抑制剂诱导头颈癌凋亡的机制分析
- 批准号:
23K15866 - 财政年份:2023
- 资助金额:
$ 3.71万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Interrogating the Fgl2-FcgRIIB axis: A novel mechanism mediating apoptosis of tumor-specific memory CD8+ T cells
探究 Fgl2-FcgRIIB 轴:介导肿瘤特异性记忆 CD8 T 细胞凋亡的新机制
- 批准号:
10743485 - 财政年份:2023
- 资助金额:
$ 3.71万 - 项目类别:
Investigating the role of apoptosis-resistance and the tumor environment on development and maintenance of sacrococcygeal teratomas
研究细胞凋亡抗性和肿瘤环境对骶尾部畸胎瘤发生和维持的作用
- 批准号:
10749797 - 财政年份:2023
- 资助金额:
$ 3.71万 - 项目类别:
The effects of glucose on immune cell apoptosis and mitochondrial membrane potential and the analysis of its mechanism by which glucose might modulate the immune functions.
葡萄糖对免疫细胞凋亡和线粒体膜电位的影响及其调节免疫功能的机制分析。
- 批准号:
22K09076 - 财政年份:2022
- 资助金额:
$ 3.71万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
XAF1 IN P53 SIGNALING, APOPTOSIS AND TUMOR SUPPRESSION
P53 信号传导、细胞凋亡和肿瘤抑制中的 XAF1
- 批准号:
10583516 - 财政年份:2022
- 资助金额:
$ 3.71万 - 项目类别:
Role of Thioredoxin system in regulation of autophagy-apoptosis cross talk in neurons: Uncovering Novel Molecular Interactions.
硫氧还蛋白系统在神经元自噬-凋亡串扰调节中的作用:揭示新的分子相互作用。
- 批准号:
RGPIN-2019-05371 - 财政年份:2022
- 资助金额:
$ 3.71万 - 项目类别:
Discovery Grants Program - Individual














{{item.name}}会员




